Research AI

Scans

Tools

Watchlists

Home

Charts

Watchlist

Products

Beta Drugs Ltd

BETA

NSE

₹1,719.60-3.56%19 Oct 2026

Reports

Pharma Formulations

Beta Drugs Ltd

BETA

NSE

₹1,719.60

-3.56%

19 Oct 2026

SOICxStockScans Reports

Ask AI

Pharma Formulations

Indices

Quick Ratios

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Peer Comparison

Quick Ratios

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Peer Comparison

Price

Charts

Documents

Edit Ratios

Mkt Cap

Market Capitalization

₹1,925Cr

Close Price

₹1,736.30

Industry

Pharma Formulations

Price To Earnings

39.27

Price To Sales

4.69

Revenue

₹410Cr

Rev Gr TTM

Revenue Growth TTM

—

PAT Gr TTM

PAT Growth TTM

—

Upcoming Results on

22 Oct 2026

Consolidated

Standalone

Numbers

Percentage

Quarter	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue RevenueCr	88	94	100	103	87	94	126
Growth YoY Revenue Growth YoY%					-1.2	0.2	25.3
Expenses ExpensesCr	70	76	81	82	70	76	98
Operating Profit Operating ProfitCr	18	17	20	21	17	18	27
OPM OPM%	20.9	18.5	19.7	20.6	19.5	18.8	21.8
Other Income Other IncomeCr	-1	2	3	3	2	3	2
Interest Expense Interest ExpenseCr	2	3	3	4	4	4	3
Depreciation DepreciationCr	3	4	4	4	4	5	4
PBT PBTCr	12	12	16	16	10	12	22
Tax TaxCr	3	3	4	4	2	3	6
PAT PATCr	9	9	12	12	9	9	16
Growth YoY PAT Growth YoY%					-4.8	0.2	40.9
NPM NPM%	10.1	9.6	11.7	11.8	9.8	9.6	13.1
EPS EPS₹	9.3	9.4	11.6	12.1	8.4	8.9	14.8

Quarter	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue RevenueCr	88	94	100	103	87	94	126
Growth YoY Revenue Growth YoY%					-1.2	0.2	25.3
Expenses ExpensesCr	70	76	81	82	70	76	98
Operating Profit Operating ProfitCr	18	17	20	21	17	18	27
OPM OPM%	20.9	18.5	19.7	20.6	19.5	18.8	21.8
Other Income Other IncomeCr	-1	2	3	3	2	3	2
Interest Expense Interest ExpenseCr	2	3	3	4	4	4	3
Depreciation DepreciationCr	3	4	4	4	4	5	4
PBT PBTCr	12	12	16	16	10	12	22
Tax TaxCr	3	3	4	4	2	3	6
PAT PATCr	9	9	12	12	9	9	16
Growth YoY PAT Growth YoY%					-4.8	0.2	40.9
NPM NPM%	10.1	9.6	11.7	11.8	9.8	9.6	13.1
EPS EPS₹	9.3	9.4	11.6	12.1	8.4	8.9	14.8

Consolidated

Standalone

Numbers

Percentage

Financial Year	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Revenue RevenueCr	51	66	91	116	184	227	296	362	385	410
Growth Revenue Growth%		30.4	37.7	27.9	58.3	23.5	30.2	22.5	6.2
Expenses ExpensesCr	41	54	73	91	141	174	236	288	309	327
Operating Profit Operating ProfitCr	9	12	18	25	43	53	60	75	76	83
OPM OPM%	18.7	17.9	19.7	21.3	23.2	23.4	20.3	20.6	19.7	20.3
Other Income Other IncomeCr	0	0	0	1	1	1	1	2	11	10
Interest Expense Interest ExpenseCr	1	1	3	2	2	2	3	7	15	15
Depreciation DepreciationCr	2	3	4	7	7	10	10	13	17	18
PBT PBTCr	7	8	12	16	34	41	49	57	54	61
Tax TaxCr	0	0	3	4	9	10	12	15	13	15
PAT PATCr	7	8	9	12	25	31	36	42	41	46
Growth PAT Growth%		18.9	17.1	24.5	111.8	23.7	18.6	16.4	-2.2
NPM NPM%	13.4	12.2	10.4	10.1	13.5	13.5	12.3	11.7	10.8	11.3
EPS EPS₹	7.8	8.9	9.5	11.6	25.8	30.4	37.9	42.0	40.9	44.2

Financial Year	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Revenue RevenueCr	51	66	91	116	184	227	296	362	385	410
Growth Revenue Growth%		30.4	37.7	27.9	58.3	23.5	30.2	22.5	6.2
Expenses ExpensesCr	41	54	73	91	141	174	236	288	309	327
Operating Profit Operating ProfitCr	9	12	18	25	43	53	60	75	76	83
OPM OPM%	18.7	17.9	19.7	21.3	23.2	23.4	20.3	20.6	19.7	20.3
Other Income Other IncomeCr	0	0	0	1	1	1	1	2	11	10
Interest Expense Interest ExpenseCr	1	1	3	2	2	2	3	7	15	15
Depreciation DepreciationCr	2	3	4	7	7	10	10	13	17	18
PBT PBTCr	7	8	12	16	34	41	49	57	54	61
Tax TaxCr	0	0	3	4	9	10	12	15	13	15
PAT PATCr	7	8	9	12	25	31	36	42	41	46
Growth PAT Growth%		18.9	17.1	24.5	111.8	23.7	18.6	16.4	-2.2
NPM NPM%	13.4	12.2	10.4	10.1	13.5	13.5	12.3	11.7	10.8	11.3
EPS EPS₹	7.8	8.9	9.5	11.6	25.8	30.4	37.9	42.0	40.9	44.2

Consolidated

Standalone

Numbers

Percentage

Financial Year	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital Equity CapitalCr	9	9	10	10	10	10	10	10	10
Reserves ReservesCr	24	32	48	59	83	113	148	187	235
Current Liabilities Current LiabilitiesCr	14	32	37	33	49	63	85	103	108
Non Current Liabilities Non Current LiabilitiesCr	3	9	13	16	17	13	12	136	143
Total Liabilities Total LiabilitiesCr	50	83	107	118	158	198	254	436	496
Current Assets Current AssetsCr	32	43	56	68	97	128	178	331	335
Non Current Assets Non Current AssetsCr	17	40	51	49	61	71	76	105	161
Total Assets Total AssetsCr	50	83	107	118	158	198	254	436	496

Financial Year	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital Equity CapitalCr	9	9	10	10	10	10	10	10	10
Reserves ReservesCr	24	32	48	59	83	113	148	187	235
Current Liabilities Current LiabilitiesCr	14	32	37	33	49	63	85	103	108
Non Current Liabilities Non Current LiabilitiesCr	3	9	13	16	17	13	12	136	143
Total Liabilities Total LiabilitiesCr	50	83	107	118	158	198	254	436	496
Current Assets Current AssetsCr	32	43	56	68	97	128	178	331	335
Non Current Assets Non Current AssetsCr	17	40	51	49	61	71	76	105	161
Total Assets Total AssetsCr	50	83	107	118	158	198	254	436	496

Consolidated

Standalone

Financial Year	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow Operating Cash FlowCr	17	0	8	19	30	23	31	36	37
Investing Cash Flow Investing Cash FlowCr	-11	-21	-15	-6	-22	-19	-14	-36	-51
Financing Cash Flow Financing Cash FlowCr	5	12	9	-8	-1	-2	-7	118	-8
Net Cash Flow Net Cash FlowCr	12	-9	2	5	7	2	9	118	-22
Free Cash Flow Free Cash FlowCr	9	-21	-7	13	10	5	19	-1
CFO To PAT CFO To PAT%	252.9	1.4	89.4	158.6	119.3	76.1	84.9	85.2	89.9
CFO To EBITDA CFO To EBITDA%	180.9	0.9	47.0	75.2	69.4	44.0	51.5	48.5	49.3

Financial Year	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow Operating Cash FlowCr	17	0	8	19	30	23	31	36	37
Investing Cash Flow Investing Cash FlowCr	-11	-21	-15	-6	-22	-19	-14	-36	-51
Financing Cash Flow Financing Cash FlowCr	5	12	9	-8	-1	-2	-7	118	-8
Net Cash Flow Net Cash FlowCr	12	-9	2	5	7	2	9	118	-22
Free Cash Flow Free Cash FlowCr	9	-21	-7	13	10	5	19	-1
CFO To PAT CFO To PAT%	252.9	1.4	89.4	158.6	119.3	76.1	84.9	85.2	89.9
CFO To EBITDA CFO To EBITDA%	180.9	0.9	47.0	75.2	69.4	44.0	51.5	48.5	49.3

Consolidated

Standalone

Financial Year	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Current
Valuation Ratios Valuation Ratios
Market Cap Market CapitalizationCr	109	91	38	115	544	603	1,186	1,924	1,206	1,925
Price To Earnings Price To Earnings	16.1	11.3	4.1	9.8	21.9	19.6	32.5	45.4	29.1	39.3
Price To Sales Price To Sales	2.2	1.4	0.4	1.0	3.0	2.6	4.0	5.3	3.1	4.7
Price To Book Price To Book	3.3	2.2	0.7	1.7	5.9	4.9	7.5	9.8	4.9	7.8
EV To EBITDA EV To EBITDA	10.9	8.9	3.0	4.8	12.7	11.3	19.5	25.6	16.2	24.0
Profitability Ratios Profitability Ratios
GPM GPM%	32.7	36.5	39.2	37.8	38.8	42.6	38.6	41.4
OPM OPM%	18.7	17.9	19.7	21.3	23.2	23.4	20.3	20.6	19.7	20.3
NPM NPM%	13.4	12.2	10.4	10.1	13.5	13.5	12.3	11.7	10.8	11.3
ROCE ROCE%	20.1	15.9	18.9	22.1	33.2	31.3	30.7	19.4	17.8	17.8
ROE ROE%	20.6	19.6	16.5	17.1	26.9	25.0	23.2	21.5	16.9	16.9
ROA ROA%	13.6	9.7	8.8	10.0	15.7	15.5	14.3	9.7	8.4	8.4
Operational Ratios Operational Ratios
Solvency Ratios Solvency Ratios
Liquidity Ratios Liquidity Ratios

Financial Year	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Current
Valuation Ratios Valuation Ratios
Market Cap Market CapitalizationCr	109	91	38	115	544	603	1,186	1,924	1,206	1,925
Price To Earnings Price To Earnings	16.1	11.3	4.1	9.8	21.9	19.6	32.5	45.4	29.1	39.3
Price To Sales Price To Sales	2.2	1.4	0.4	1.0	3.0	2.6	4.0	5.3	3.1	4.7
Price To Book Price To Book	3.3	2.2	0.7	1.7	5.9	4.9	7.5	9.8	4.9	7.8
EV To EBITDA EV To EBITDA	10.9	8.9	3.0	4.8	12.7	11.3	19.5	25.6	16.2	24.0
Profitability Ratios Profitability Ratios
GPM GPM%	32.7	36.5	39.2	37.8	38.8	42.6	38.6	41.4
OPM OPM%	18.7	17.9	19.7	21.3	23.2	23.4	20.3	20.6	19.7	20.3
NPM NPM%	13.4	12.2	10.4	10.1	13.5	13.5	12.3	11.7	10.8	11.3
ROCE ROCE%	20.1	15.9	18.9	22.1	33.2	31.3	30.7	19.4	17.8	17.8
ROE ROE%	20.6	19.6	16.5	17.1	26.9	25.0	23.2	21.5	16.9	16.9
ROA ROA%	13.6	9.7	8.8	10.0	15.7	15.5	14.3	9.7	8.4	8.4
Operational Ratios Operational Ratios
Solvency Ratios Solvency Ratios
Liquidity Ratios Liquidity Ratios

	FREDUN	INDOCO	SAIPARENT	BETA	ACCENTMIC	AMRUTANJAN	JAGSNPHARM
Market CapitalizationMkt CapCr	2,373	2,177	2,133	1,925	1,564	1,448	1,438
Close PriceClose₹	1,435.00	235.90	482.75	1,736.30	652.00	501.00	217.95
IndustryIndustry	Pharma Formulations	Pharma Formulations	Pharma Formulations	Pharma Formulations	Pharma Formulations	Pharma Formulations	Pharma Formulations
Price To EarningsPE	50.23	737.19	102.71	39.27	27.23	26.83	32.05
Price To SalesPS	3.17	1.16	5.60	4.69	4.07	2.83	4.89
RevenueRevenueCr	748	1,873	381	410	385	511	294
Revenue Growth TTMRev Gr TTM%		12.0%			38.4%	10.7%	3.9%
PAT Growth TTMPAT Gr TTM%		102.7%			64.2%	-1.1%	-25.3%

	FREDUN	INDOCO	SAIPARENT	BETA	ACCENTMIC	AMRUTANJAN	JAGSNPHARM
Market CapitalizationMkt CapCr	2,373	2,177	2,133	1,925	1,564	1,448	1,438
Close PriceClose₹	1,435.00	235.90	482.75	1,736.30	652.00	501.00	217.95
IndustryIndustry	Pharma Formulations	Pharma Formulations	Pharma Formulations	Pharma Formulations	Pharma Formulations	Pharma Formulations	Pharma Formulations
Price To EarningsPE	50.23	737.19	102.71	39.27	27.23	26.83	32.05
Price To SalesPS	3.17	1.16	5.60	4.69	4.07	2.83	4.89
RevenueRevenueCr	748	1,873	381	410	385	511	294
Revenue Growth TTMRev Gr TTM%		12.0%			38.4%	10.7%	3.9%
PAT Growth TTMPAT Gr TTM%		102.7%			64.2%	-1.1%	-25.3%